Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of bryostatin 1 plus vincristine in treating
patients who have recurrent or refractory lymphoma. Drugs used in chemotherapy use different
ways to stop cancer cells from dividing so they stop growing or die. Bryostatin 1 may help
vincristine kill more cancer cells by making them more sensitive to the drug